Crinetics Pharmaceuticals Inc (NAS:CRNX)
$ 46.81 -0.66 (-1.39%) Market Cap: 3.69 Bil Enterprise Value: 2.90 Bil PE Ratio: 0 PB Ratio: 4.20 GF Score: 33/100

Crinetics Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 11:45PM GMT
Release Date Price: $37.92 (+5.48%)
Jessica Fye J.P. Morgan;Analyst

Good afternoon everyone. My name is Jessica Fye, Senior Biotech Analyst at J.P. Morgan, and we're continuing the 42 Annual Health Care Conference today with Crinetics. I'm joined by the company's CEO, Scott Struthers. He's going to give a presentation on the business and then we're going to go into Q&A after that, if you want to answer the question in the room, raise your hand and someone will bring you a microphone or alternatively, you can send questions through the portal ad over here. And so with that, let me turn it over to Scott.

Scott Struthers Crinetics Pharmaceuticals Inc;Founder;CEO

&

Thanks, Jess. Good afternoon, everybody. Thanks for having me and thanks for coming. Thanks to those you've supported us through the years. I'll refer you to our forward-looking statements, of course, which I'm sure you have all read carefully.

So since the last time I was here a year ago, we're a very different company. The strategy we've been following since the beginning of the company hasn

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot